Company intelligence / Profile preview

ARIVA Med

Ownership: Private
Development stage: Preclinical

Overview

AREVA Med develops targeted alpha therapies using lead‑212 radioisotope technology. In partnership with Nordic Nanovector, it has advanced a program targeting CD37 for leukemia treatment. The company opened a Texas facility for 212Pb production and continues to expand its pipeline in oncology. No published late-stage clinical results are available as of the last update.

Therapeutic areas: Oncology
Modalities: Targeted alpha therapies using radioisotopes (notably lead‑212 conjugates)
Industry: Biotech

Drug pipeline

2 assets

AR-7732

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Nordic Nanovector (collaboration on anti-CD37 antibody conjugated with lead‑212)

Beyond the preview

Go deeper on ARIVA Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARIVA Med.

Explore the full profile